Literature DB >> 25598822

Serotonin and mental disorders: a concise review on molecular neuroimaging evidence.

Shih-Hsien Lin1, Lan-Ting Lee2, Yen Kuang Yang1.   

Abstract

Serotonin is one of the most important neurotransmitters influencing mental health and, thus, is a potential target for pharmaco-logical treatments. Functional neuroimaging techniques, such as positron-emission tomography (PET) and single photon emission computed tomography (SPECT), could provide persuasive evidence for the association between mental disorders and serotonin. In this concise review, we focus on evidence of the links between serotonin and major depressive disorders, as well as other mood disorders, anxiety disorders, schizophrenia, addiction, attention deficit hyperactivity disorder (ADHD), and autism.

Entities:  

Keywords:  Mental disorders; Positron-emission tomography; Serotonin; Single photon emission computed tomography

Year:  2014        PMID: 25598822      PMCID: PMC4293164          DOI: 10.9758/cpn.2014.12.3.196

Source DB:  PubMed          Journal:  Clin Psychopharmacol Neurosci        ISSN: 1738-1088            Impact factor:   2.582


INTRODUCTION

Serotonin is one of the most important neurotransmitters influencing mental health.1) Most serotonin is distributed outside of the central nervous system (CNS), and influences a wide range of physiologic processes in many organs.2) However, the 2% of serotonin that is present in the CNS plays a pivotal role in the etiology of many mental disorders. Both receptors and transporters play important roles in synapses. 5-Hydroxytryptamine (5-HT) receptors are activated by the serotonin neurotransmitter, while the 5-HT transporter reuptakes the serotonin neuro-transmitter from the synaptic cleft. Altered receptor and/or serotonin transporter (SERT) function may be associated with mental disorders. The development of selective serotonin reuptake inhibitors (SSRIs) illustrates the importance of the serotonergic system with regard to the treatment of mental disorders. Further, the discovery of the role that the serotonin-transporter-linked polymorphic region (5-HTTLPR) plays in the association between stress and mental health highlights the pervasive influence of the serotonin transporter gene. Meanwhile, noninvasive neuroimaging techniques, such as positron-emission tomography (PET) and single photon emission computed tomography (SPECT), can be used to study regional receptor and transporter concentrations in specific brain areas. These are important tools that can be used to acquire in vivo brain images and quantitative measurements with regard to the activities of the serotonergic system.3,4) Although there are many families of 5-HT receptors, most studies rely on radioligands for 5-HT1A and 5-HT2A. Some of the important radioligands used to study the serotonergic system are shown in Table 1. For instance, [11C]WAY-100635 may be the most important radioligand for 5-HT1A; however, there are also other available radioligands. Several radioligands were also developed for 5-HT2A. For SERT, Beta-[123I]CIT is one of the most useful radioligands for the SPECT. However, this radiotracer binds both on SERT and dopamine transporter (DAT). Another important radiotracer for SEPCT is [123I]ADAM, which selectively binding on SERT only. [11C]DASB and [11C]MADAM are important radioligands for PET. Evidence from neuroimaging studies may enhance our understanding of the role of serotonin in many mental disorders, and the aim of this essay was thus to provide a concise and updated review of the literature on this topic.
Table 1

Important PET and SPECT radioligands for serotonergic targets (5-HT1A, 5-HT2A, and SERT) in humans.

PET, positron-emission tomography; SPECT, single photon emission computed tomography; 5-HT, 5-hydroxytryptamine; SERT, serotonin transporter.

Source: Paterson et al.3)

MAIN SUBJECTS

Major Depressive Disorder (MDD)

MDD is one of the most important mental disorders associated with altered serotonergic activity, and several extensive reviews of the literature exist on this topic.5) Drevets et al.6) used PET in conjunction with [11C] WAY-100635, and found that the binding potential of 5-HT1A receptors in the raphe and mesiotemporal cortex of unmedicated subjects with MDD was lower than that in controls. Similar results were found among medicated and unmedicated MDD subjects in other studies,7,8) as well as among patients with recurrent MDD.9) However, not all studies agree on this issue. For example, in another PET study that used the same radioligand, MDD patients using antidepressants had greater 5-HT1A receptor binding potential in the raphe and mesiotemporal cortex than controls and antidepressant-naïve patients with MDD; however, receptor binding potential was not significantly different between drug-naïve MDD patients and controls.10) All of these earlier studies indicate that serotonin receptors are associated with MDD. The role of serotonin transporters, which influence the level of serotonergic activity, has also been examined in related neuroimaging studies. While it was demonstrated that a lower level of SERT availability in the midbrain is related to MDD,11,12,13) several studies presented findings that contradicted this.14,15,16) No differences were found in SERT availability between drug-free euthymic patients with MDD and controls.17) However, our previous study demonstrated that SERT availability in the midbrain was significantly lower in subjects with a first-degree family history of MDD than in healthy subjects.18) Meanwhile, [11C]McN 5652 studies indicated a lower SERT availability binding potential in the amygdala of drug-naïve patients with MDD,19) and increased SERT availability in the left frontal cortex and right cingulate cortex among drug-free patients.20) Greater SERT availability was reportedly associated with more negative and dysfunctional attitudes among patients with MDD,21) and an increase in SERT availability in the thalamus and striatum of patients with MDD was also found in a [11C]DASB study.22) These findings are shown in Table 2. As serotonergic antidepressants are an important treatment for MDD, PET is also used to probe SSRI occupancy. SERT occupancy is approximately 80% under the effective doses in PET studies using [11C]DASB.23,24)
Table 2

The summary of the findings on major depressive disorder (MDD)

RN, raphe nuclei; AC, anterior cingulated cortex; AMY, amygdala; ANG, angular gyrus; DLP, dorsolateral prefrontal cortex; ITG, inferior temporal gyrus; MTG, middle temporal gyrus; STG, superior temporal gyrus; HIP, hippocampus; INS, insular cortex; MFC, medial prefrontal cortex; ORB, orbitofrontal cortex; PC, posterior cingulated cortex; SG, supramarginal gyrus; VLP, ventrolateral prefrontal cortex; VPFC, ventral prefrontal cortex; MPFC, medial PFC; DLPFC, dorsolateral PFC; CIN, cingulate cortex; PHG, parahippocampal gyrus; TEM, temporal cortex; PAR, parietal cortex; OCC, occipital cortex.

Other Mood Disorders

Altered serotonergic activity is associated with various other mood disorders. For example, increased SERT binding potential was found among unmedicated subjects with bipolar disorder in a PET study using [11C]DASB,25) and similar findings were also reported in another PET study focused on 5-HT1A.26) However, a decreased level of SERT availability, as assessed by SPECT with [123I] ADAM, was found in medicated subjects with euthymic bipolar I, but not bipolar II.27) We speculate that these findings indicate that SERT availability might not only be a biomarker for bipolar disorder but is also influenced by medication or disease severity. In addition, the biological characteristics of bipolar I and II are different.27) It is also worth noting that altered serotonin activity may be related to the severity of symptoms associated with bipolar disorder.25) We speculate that the mechanism between abnormal serotonegic activity and bipolar disorder may be complex.

Anxiety Disorders

Studies also indicate that serotonergic activity may be associated with anxiety disorders,28) although the evidence remains inconclusive, with some studies reporting that there is no association,29) or only an unclear one.30,31) Meanwhile, reduced SERT32) and 5-HT2A 33) binding potential was found among drug-naïve subjects with obsessive-compulsive disorder. Kent et al.34) reported that occupancy of SERT by paroxetine (a kind of SSRI) was higher in patients with social anxiety disorder. Additionally, other authors found significantly lower 5-HT1A binding potential in several limbic and paralimbic areas.30) Our preliminary small sample study of patients with generalized anxiety disorder showed no significant difference with regard to SERT level compared with a control group (Yang et al., personal communication).

Schizophrenia

Although it has been proposed that the serotonergic system may interact with the dopaminergic system in ways that may be associated with schizophrenia,35,36) there remains little neuroimaging evidence regarding this issue. There is reportedly no significant decrease in 5-HT receptors or SERT among schizophrenic subjects, based on PET studies using different radiotracers,37,38,39,40) and similar findings were also reported in a SPECT study using [123I] β-CIT.41) The role of the serotonergic system in the treatment of schizophrenia should be explored further.

Addiction

Although it has been proposed that serotonergic dysfunction may be associated with addictive behaviors,42,43) there is little evidence from neuroimaging studies, and what exists remains inconclusive. Significantly reduced SERT availability in the brain-stems of alcoholics was found with SPECT using [123I]β-CIT.44) However, another study using the same radiotracer indicated that brainstem SERT availability among smokers was higher than among non-smokers.45) Alcoholic nonsmokers reportedly had higher levels of SERT availability in the brainstem and diencephalon than controls.46) The serotonergic system might also be also associated with other harmful forms of addiction, although the detailed mechanisms remain to be elucidated. For example, the association between serotonin and heroin use is unclear, although a SPECT study with [123I]β-CIT indicated that the level of SERT availability was similar between heroin users and healthy controls.47) One of our studies48) indicated that midbrain SERT availability among opioiddependent patients being treated with low doses of methadone could be lower than that among controls and among former opioid addicts practicing methadone-free abstinence (Fig. 1). On the other hand, another study from our lab indicated that a higher level of SERT availability was associated with a greater likelihood of relapse among former heroin users.49) We speculate, therefore, that serotonin may play a number of roles in heroin addiction. For example, both biological (e.g., homeostasis of neuro-activity) and psychological factors (e.g., depressive tendency, personality traits and risk preference) might have joint effects. Altered serotonergic activity may be associated with use of other substances, such as cocaine. An animal study indicated that acute cocaine self-administration may induce higher levels of SERT availability.50) Evidence in humans is scarce. A SPECT study found elevated SERT availability in acutely abstinent patients with cocaine dependency.51) The association between serotonin and addiction remains to be elucidated.
Fig. 1

The serotonin transporter (SERT) availability for heroin users and controls. Reproduced based on Yeh et al.48)

Attention Deficit Hyperactivity Disorder (ADHD)

It was proposed that serotonin may play a role in ADHD via its interplay with the dopaminergic system.52) Additionally, there was reportedly no difference in SERT availability between treatment-naïve ADHD adults and their controls, while there was a lower level of DAT among ADHD subjects.53) Similar findings were reported in a recent small sample PET study using [11C]MADAM, which indicated that the level of SERT availability was similar between adult patients with ADHD and controls.54)

Autism

While the mechanisms of autism remain unclear, a lower level of 5-HT2A receptor binding was found among adult men with Asperger's syndrome in a small sample SPECT study.55) In a SPECT study using [123I]norβ-CIT, a significantly lower level of SERT availability in the medial frontal cortex was found among children with autism.56) More importantly, a PET study reported lower SERT levels throughout the brain in autistic men; reduced SERT level in the anterior/posterior cingulate cortex was associated with poor social cognition.57) Although there are few findings on autism in the literature, published work does shed some light on the etiology of this condition.

Other Risks Associated with Mental Problems

Neuroticism is a trait that may be associated with mood disorders. A PET study reported that a higher SERT binding potential was associated with neuroticism among healthy males.58) A higher level of frontolimbic 5-HT2A receptor binding was reportedly associated with neuroticism among subjects with a family history of mood disorders.59) However, little is known about the association between serotonin and other personality traits, although a lower SERT level was found among subjects with borderline personality disorder.60) The studies mentioned above suggest that a lower level of serotonergic activity might be associated with poor social interaction.56,57) Similarly, our recent study indicated that lower SERT availability was associated with a lower level of perceived social support,61) which is linked with stress-induced mental illness. In support of this, another of our studies also indicated that perceived stress was associated with SERT availability.62) Furthermore, hypothalamic-pituitary-adrenal (HPA) axis function, as measured by dexamethasone suppression test, was found to be associated with SERT availability in healthy subjects.63)

CONCLUSIONS

Serotonin is one of the most important neurotransmitters and, thus, is a potential target for pharmacological treatment. A large body of evidence supports the association between the serotonergic system with MDD and other mood disorders. However, while pharmacological data support the view that serotonin could be related to anxiety disorders, imaging findings remain insufficient and inconclusive. Moreover, the association between serotonin and schizophrenia, which is the most severe psychiatric disorder, has also not been demonstrated by neuroimaging studies. The association between addiction and the serotonergic system could be complex, as the direction of its effects remains unclear. At present, little evidence supports a link between serotonin and ADHD. However, a few studies suggest that altered hyposerotonergic activity might be one of the etiologies of autism. Even in healthy participants, correlations between SERT and stressful life events and stress hormones still exist, and these findings could have implications for clinical practice.
  62 in total

1.  Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study.

Authors:  Ramin V Parsey; Maria A Oquendo; R Todd Ogden; Doreen M Olvet; Norman Simpson; Yung-Yu Huang; Ronald L Van Heertum; Victoria Arango; J John Mann
Journal:  Biol Psychiatry       Date:  2005-09-09       Impact factor: 13.382

2.  Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT.

Authors:  M Laruelle; A Abi-Dargham; C van Dyck; R Gil; D C D'Souza; J Krystal; J Seibyl; R Baldwin; R Innis
Journal:  Biol Psychiatry       Date:  2000-03-01       Impact factor: 13.382

3.  Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder.

Authors:  Dara M Cannon; Masanori Ichise; Denise Rollis; Jacqueline M Klaver; Shilpa K Gandhi; Dennis S Charney; Husseini K Manji; Wayne C Drevets
Journal:  Biol Psychiatry       Date:  2007-08-02       Impact factor: 13.382

4.  Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects.

Authors:  R Lewis; S Kapur; C Jones; J DaSilva; G M Brown; A A Wilson; S Houle; R B Zipursky
Journal:  Am J Psychiatry       Date:  1999-01       Impact factor: 18.112

Review 5.  The role of serotonin in schizophrenia.

Authors:  N Iqbal; H M van Praag
Journal:  Eur Neuropsychopharmacol       Date:  1995       Impact factor: 4.600

6.  PET imaging of serotonin 1A receptor binding in depression.

Authors:  W C Drevets; E Frank; J C Price; D J Kupfer; D Holt; P J Greer; Y Huang; C Gautier; C Mathis
Journal:  Biol Psychiatry       Date:  1999-11-15       Impact factor: 13.382

7.  Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.

Authors:  J H Meyer; A A Wilson; N Ginovart; V Goulding; D Hussey; K Hood; S Houle
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

8.  Serotonin transporter availability in the midbrain and perceived social support in healthy volunteers.

Authors:  Hsiang Yu Huang; I Hui Lee; Kao Chin Chen; Shih-Hsien Lin; Tzung Lieh Yeh; Po See Chen; Nan-Tsing Chiu; We Jen Yao; Chia-Chieh Chen; Mei-Hsiu Liao; Yen Kuang Yang
Journal:  J Psychosom Res       Date:  2013-10-04       Impact factor: 3.006

Review 9.  Dopamine-serotonin interactions in attention-deficit hyperactivity disorder (ADHD).

Authors:  Robert D Oades
Journal:  Prog Brain Res       Date:  2008       Impact factor: 2.453

Review 10.  5-HT radioligands for human brain imaging with PET and SPECT.

Authors:  Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen
Journal:  Med Res Rev       Date:  2011-06-14       Impact factor: 12.944

View more
  34 in total

1.  Generation of functional human serotonergic neurons from fibroblasts.

Authors:  K C Vadodaria; J Mertens; A Paquola; C Bardy; X Li; R Jappelli; L Fung; M C Marchetto; M Hamm; M Gorris; P Koch; F H Gage
Journal:  Mol Psychiatry       Date:  2015-10-27       Impact factor: 15.992

2.  Stress exposure and psychopathology alter methylation of the serotonin receptor 2A (HTR2A) gene in preschoolers.

Authors:  Stephanie H Parade; Andrew M Novick; Justin Parent; Ronald Seifer; Samantha J Klaver; Carmen J Marsit; Asi Polly Gobin; Bao-Zhu Yang; Audrey R Tyrka
Journal:  Dev Psychopathol       Date:  2017-12

Review 3.  Looking Beyond the 5-HTTLPR Polymorphism: Genetic and Epigenetic Layers of Regulation Affecting the Serotonin Transporter Gene Expression.

Authors:  Sandra Iurescia; Davide Seripa; Monica Rinaldi
Journal:  Mol Neurobiol       Date:  2016-12-08       Impact factor: 5.590

4.  Serotonin disruption at gestation alters expression of genes associated with serotonin synthesis and reuptake at weaning.

Authors:  M C Fabio; I J C Servin-Bernal; A L Degano; R M Pautassi
Journal:  Psychopharmacology (Berl)       Date:  2022-09-05       Impact factor: 4.415

5.  Transient serotonin depletion at adolescence, but not at early infancy, reduced subsequent anxiety-like behavior and alcohol intake in female mice.

Authors:  Fabio Bellia; Andrea Suarez; Claudio D'Addario; Ricardo Marcos Pautassi; María Carolina Fabio
Journal:  Psychopharmacology (Berl)       Date:  2020-10-04       Impact factor: 4.530

Review 6.  Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.

Authors:  C E Van Skike; S E Maggio; A R Reynolds; E M Casey; M T Bardo; L P Dwoskin; M A Prendergast; K Nixon
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-11-12       Impact factor: 5.067

Review 7.  The Roles of Serotonin in Neuropsychiatric Disorders.

Authors:  Mahsa Pourhamzeh; Fahimeh Ghasemi Moravej; Mehrnoosh Arabi; Elahe Shahriari; Soraya Mehrabi; Richard Ward; Reza Ahadi; Mohammad Taghi Joghataei
Journal:  Cell Mol Neurobiol       Date:  2021-03-02       Impact factor: 5.046

8.  Deprenyl reduces inflammation during acute SIV infection.

Authors:  K M Emanuel; K Runner; Z D Brodnik; B M Morsey; B G Lamberty; H S Johnson; A Acharya; S N Byrareddy; R A España; H S Fox; P J Gaskill
Journal:  iScience       Date:  2022-04-06

Review 9.  Changing the Cortical Conductor's Tempo: Neuromodulation of the Claustrum.

Authors:  Kelly L L Wong; Aditya Nair; George J Augustine
Journal:  Front Neural Circuits       Date:  2021-05-13       Impact factor: 3.492

10.  Environment-Sensitive Fluorescence of 7-Nitrobenz-2-oxa-1,3-diazol-4-yl (NBD)-Labeled Ligands for Serotonin Receptors.

Authors:  Parijat Sarkar; Kaleeckal G Harikumar; Satinder S Rawat; Sanjib Das; Tushar K Chakraborty; Amitabha Chattopadhyay
Journal:  Molecules       Date:  2021-06-24       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.